g03-52-01
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2020 (NCT04171115)
Timeline
Indications
Mechanism of action
- Botulinum neurotoxin type AImmunity, passive
botA immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05348993 | Phase 2 | Jun 29, 2022 | Department of Defense, Ology Bioservices |
| NCT04171115 | Phase 1 | Apr 1, 2020 | Department of Defense, ICON, Ology Bioservices |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Department of Defense | Government | 2 | 0 | 2 | 2020 |
| Ology Bioservices | For profit | 2 | 2 | 2 | 2020 |
| ICON | For profit | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1